Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Journal for Immunotherapy of Cancer
Young Kwang ChaeFrancis Giles

Abstract

Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being...Continue Reading

References

Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
May 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·E L MastellerC B Thompson
Apr 3, 2001·The Journal of Experimental Medicine·S Y TsengH Tsuchiya
Jun 28, 2002·Nature Immunology·Jackson G EgenJames P Allison
Aug 28, 2002·Immunity·Alison V CollinsSimon J Davis
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
May 4, 2004·Nature Reviews. Immunology·Lieping Chen
Aug 18, 2004·The Journal of Clinical Investigation·Alan N Houghton, José A Guevara-Patiño
Oct 18, 2005·Molecular and Cellular Biology·Richard V ParryJames L Riley
Apr 12, 2006·The Journal of Experimental Medicine·Mary E KeirArlene H Sharpe
Mar 28, 2007·Immunology·Ryungsa KimKazuaki Tanabe
May 4, 2007·The Journal of Clinical Investigation·Jeremy B Swann, Mark J Smyth
Jul 31, 2007·Seminars in Cancer Biology·Jennifer M ReimanKeith L Knutson
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Jul 11, 2008·Expert Opinion on Biological Therapy·Michael Boyiadzis, Kenneth A Foon
May 23, 2009·British Journal of Pharmacology·Patrick ChamesDaniel Baty
Feb 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Michael A CurranJames P Allison
Apr 9, 2011·New Biotechnology·Vinochani PillayAndrew M Scott
Jun 1, 2011·Cancer Immunology, Immunotherapy : CII·Isabel PoschkeRolf Kiessling
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Aug 29, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C G Drake
Dec 18, 2012·Oncoimmunology·Laurence Zitvogel, Guido Kroemer
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory L Beatty, Whitney L Gladney
Dec 30, 2014·Oncotarget·Lorenzo GalluzziGuido Kroemer
Feb 14, 2015·Clinical Pharmacology and Therapeutics·C E SteuerD R Gandara
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 2, 2015·The Journal of Clinical Investigation·Lieping Chen, Xue Han
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai

❮ Previous
Next ❯

Citations

Jul 27, 2018·Journal of Clinical Pharmacy and Therapeutics·Gregory M PetersonInger H Olesen
Aug 31, 2018·Clinical and Experimental Pharmacology & Physiology·Chunguo CuiZecheng Yang
Dec 26, 2018·Clinical and Experimental Immunology·A PawłowskaI Wertel
Apr 25, 2019·Journal of Hematology & Oncology·Dongxu WangHaitao Zhao
Jan 30, 2019·Internal Medicine Journal·Brett HamiltonRob Zielinski
May 28, 2019·Minerva medica·Giacomo CorradoGabriella Ferrandina
Apr 2, 2019·Current Topics in Medicinal Chemistry·Wenjie Wang, Yuk-Ching Tse-Dinh
Oct 4, 2019·Therapeutic Advances in Medical Oncology·Tucci MarcoSilvestris Franco
Jan 12, 2020·Molecular Biology Reports·Feng TangBing Zhao
Feb 14, 2020·Science Translational Medicine·Candice R GurbatriTal Danino
Jul 6, 2019·ESMO Open·Alex FriedlaenderGiuseppe Banna
Apr 11, 2020·Molecular Carcinogenesis·J Jason MortonAntonio Jimeno
Aug 6, 2020·Cells·Jenny SprootenAbhishek D Garg
Nov 8, 2018·Experimental and Therapeutic Medicine·Linlin Zhang, Shuangquan Yu
Apr 13, 2019·Journal of Experimental & Clinical Cancer Research : CR·N A SeebacherA M Merlot
Oct 16, 2019·The Breast Journal·Michela PalleschiAndrea Rocca
Dec 11, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wesley F TaylorEhsan Jabbarzadeh
Nov 22, 2019·Frontiers in Oncology·Marco TucciFrancesco Silvestris
Apr 23, 2019·Journal of Diabetes Research·Peng SunFang Guo
Oct 2, 2019·Clinical & Translational Immunology·William C DougallMark J Smyth
Dec 5, 2019·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Mohit Pratap SinghAshish Ranjan

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01927419
NCT01024231
NCT02723006
NCT02935790
NCT01940809
NCT02941744
NCT02913417
NCT02857569
NCT02736123
NCT02089685

Software Mentioned

SECOMBIT

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Related Papers

BioMed Research International
Ayumu ItoShigehisa Kitano
Journal of the Chinese Medical Association : JCMA
Yuh-Min Chen
Annals of Oncology : Official Journal of the European Society for Medical Oncology
J NaidooJedd D Wolchok
© 2022 Meta ULC. All rights reserved